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Abstract
Background: The complement factor H (CFH) gene has been recently confirmed to play an
essential role in the development of age-related macular degeneration (AMD). There are conflicting
reports of its role in coronary heart disease. This study was designed to investigate if, using a family-
based approach, there was an association between genetic variants of the CFH gene and risk of
early-onset coronary heart disease.
Methods: We evaluated 6 SNPs and 5 common haplotypes in the CFH gene amongst 1494
individuals in 580 Irish families with at least one member prematurely affected with coronary heart
disease. Genotypes were determined by multiplex SNaPshot technology.
Results: Using the TDT/S-TDT test, we did not find an association between any of the individual
SNPs or any of the 5 haplotypes and early-onset coronary heart disease.
Conclusion: In this family-based study, we found no association between the CFH gene and early-
onset coronary heart disease.
Background
Coronary heart disease (CHD) remains a leading cause of
death worldwide. It is a complex disorder stemming from
interactions between multiple genetic and environmental
risk factors. There is increasing evidence that one of the
key factors generating and maintaining inflammation in
the arterial intima is the complement system [1]. Recently,
the amount of complement factor H (CFH) was found to
be much greater in the superficial layer of human coro-
nary atherosclerotic lesions than in the deeper layers, indi-
cating a potential role of CFH in atherogenesis [2].
CFH is encoded by a single gene (CFH) on human chro-
mosome 1q32. Polymorphisms in this gene have been
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confirmed to be strongly associated with age-related mac-
ular degeneration (AMD) [3-7]. It is suggested that the
variants in this gene influence the levels of CFH expres-
sion. For example, the Y402H (rs1061170) polymor-
phism, which is located within binding sites for heparin
and C-reactive protein (CRP) [8], was found to change the
binding properties and have functional implications [9],
whilst the I62V (rs800292) polymorphism is located in
exon 2, which contains a C3b binding site [6]. These alter-
ations may lead to complement related damage to blood
vessels [4]. CFH variants with more substantial effects
may be implicated in the earlier age-of-onset of certain
diseases [6]. In 2006, Kardys and colleagues investigated
the role of the Y402H polymorphism in the CFH gene and
reported an increased risk for myocardial infarction in
those who were homozygous for the His variant [10].
However, three subsequent studies have not been able to
replicate this result [11-13].
In our study, we investigated the role of CFH gene poly-
morphisms as risk markers for early-onset CHD in a well-
characterised Irish family-based study.
Methods
Study population
The entry criteria used in this study have been described
elsewhere [14]. Between August 1999 and October 2004
we recruited 1494 individuals from 580 families. All sub-
jects were Caucasian whose four grandparents were born
in Ireland. Each family had at least one member affected
with early-onset CHD (disease onset ≤55 years for males
and ≤60 years for females) and at least one unaffected sib-
ling and/or both parents surviving.
The affected individuals were recruited from the cardiol-
ogy units of the Royal Victoria Hospital and Belfast City
Hospital, Northern Ireland. CHD was defined as the pres-
ence of one or more of the following features: (1) a history
of acute MI (as defined by WHO criteria); (2) a history of
unstable angina (typical chest pain with dynamic ECG
changes or minor elevations in cardiac markers); (3) cor-
onary artery disease angiographically (≥ 70% luminal ste-
nosis).
Unaffected siblings were required to: (1) be older than the
affected sibling was at the onset of CHD; (2) have no
symptoms of angina or possible MI by WHO question-
naire assessments [15]; (3) have no history of CHD diag-
nosed by a doctor; and (4) have a resting 12 lead ECG lead
showing no evidence of ischaemia or previous MI [16].
All subjects underwent physical examination and pro-
vided demographic information and medical history
(including CHD risk factors) using standardised question-
naires.
The study was approved by the Research Ethics Commit-
tee of Queen's University Belfast and informed consent
was obtained from all subjects.
DNA extraction and genotyping
DNA was extracted from peripheral whole blood using a
salting out method. Genotype determination was per-
formed using multiplex SNaPshot technology, an ABI flu-
orescence-based assay allelic discrimination method
(Applied Biosystems, USA). Genotyping was repeated in
10% of the samples randomly selected as a quality control
measure. Two observers unaware of the subject's disease
status read each gel image. GeneMarkerV1.5 (Softgenetics,
USA) was used to determine each allele.
Statistical analysis
The combined TDT/S-TDT test [17,18] was used to assess
the presence of linkage disequilibrium between the 6
SNPs or 5 haplotypes and early-onset CHD by testing for
unequal transmission of an allele or haplotype from par-
ents to affected offspring or unequal sharing of an allele or
haplotype within disease-discordant sibships.
The combined TDT/S-TDT combines the TDT with the sib-
ling TDT (S-TDT). Trios are informative for the TDT if
there is an affected child and at least one parent is hetero-
zygous. Sib pairs are informative for the S-TDT if there is
at least one affected and one unaffected sibling with dif-
ferent marker genotypes.
Analysis of variance was used to compare means for quan-
titative variables and the chi-squared test was used for
qualitative variables. SPSS 14.0 (SPSS Inc, USA) was used
for these statistical analyses.
All statistical tests were performed at the 5% significance
level (two-tailed).
Results
A total of 1494 individuals from 580 families were
included (800 discordant sib-pairs and 64 parent-child
trios). Table 1 shows the family structures of the partici-
pants. Of note, there are more male probands and more
female siblings, which reflect the earlier onset of CHD in
men compared with women (Table 2). Smoking and dia-
betes are more common in the probands; however, hyper-
tension and elevated levels of total cholesterol were less
common in the probands, probably reflecting pharmaco-
logical intervention in the patient group (Table 2). TDT/S-
TDT results at the single SNP level are shown in Table 3.
No transmission distortion was detected for any of the
tested SNPs. Table 4 shows the association analysis of
CFH gene haplotypes. No association between any of the
haplotypes and early-onset CHD was found.BMC Medical Genetics 2007, 8:62 http://www.biomedcentral.com/1471-2350/8/62
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Discussion
There is evidence that polymorphisms in the CFH gene
may be involved in atherogenesis [19]. The CFH gene is a
member of the Regulator of Complement Activation
(RCA) gene cluster [5]. The activation of the complement
system is an important link between inflammation and
atherogenesis. It has been postulated that variants in the
CFH gene may be associated with CHD through modula-
tion of inflammatory pathways, as has been reported in
age-related macular degeneration (AMD) patients [4].
The CFH gene has been found to contribute around 50%
percent of the risk of AMD [5]. AMD and atherosclerotic
cardiovascular disease appear to share common patho-
genic mechanisms: both are characterized by lipid deposi-
tion (drusen and plaques) and thickening of connective
tissue (Bruch's membrane and arterial intima) [20]. One
possible pathogenic mechanism is that the normal role of
CFH is to prevent uncontrolled complement activation
and inflammation [6]. Hence, mutations in CFH may
increase inflammation and its pathological consequences.
However, there is evidence that the mechanisms of
atherogenesis may vary according to the size of arteries,
which means that whilst CFH genetic variants may con-
tribute to the atherogenesis in the tiny vessels in the eye,
they may not have the same effect in the coronary arteries
[21].
A recent study in Netherlands showed that the Y402H pol-
ymorphism was associated with increased risk of myocar-
dial infarction. The HH homozygotes had a hazard ratio
of 1.77 (95% confidence interval 1.23 to 2.55) [10]. They
first excluded the non-MI CHD patients (13% of the study
population). In their case-control study, using samples
from the Physicians' Health Study, Zee et al did not find
any association between the CFH Y402H gene polymor-
phism and incident myocardial infarction, ischaemic
stroke, or venous thromboembolism [11]. Using samples
from the Atherogene and ECTIM studies, Nicaud and col-
leagues were also unable to find any association between
common polymorphisms in the CFH and coronary artery
disease [12]. Likewise, in their study of 1170 patients with
angiographically confirmed coronary artery disease and
560 controls, Goverdhan and co-workers did not detect
any association between the CFH Y402H gene variant and
presence or severity of CAD [13]. Such non-replication of
findings is a common finding in the field of the genetics
of complex disease [22].
One possible explanation for the lack of association in
some of these reported studies is that CFH may be
involved more in the formation of unstable plaques rather
than the more stable atherosclerotic lesions. A significant
characteristic of unstable lesions is the presence of numer-
ous macrophages with matrix metalloproteinases, which
can digest the fibrous cap part of the plaque. In the paper
by Sivaprasad and colleagues, 3-fold increases of matrix
metalloproteinase-9 were found in the AMD patients
[23]. This function may be mediated in part by C-Reactive
Protein, which has been reported to be associated with
unstable atherosclerotic lesions [24]. Another supporting
study showed that the activation of CFH is greater in the
superficial rather than the deeper layer of the atheroscle-
rotic plaque [2].
Whilst we have shown differences in the prevalence of
conventional risk factors between the probands and sib-
lings, family-based statistical analyses are, unfortunately,
not suited to investigating gene-environment interactions
since, unlike the subjects in a case-control study, families
cannot be neatly divided into those with and those with-
Table 1: Family structures of 1494 subjects in 580 families
Number of families Number of 
individuals
Proband + parents + 
0 sibling
48 144
Proband + parents + 
1 sibling
93 6
Proband + parents + 
2 sibling
73 5
Proband+1 sibling 337 674
Proband+2 sibling 128 384
Proband+3 sibling 39 156
Proband+4 sibling 8 40
Proband+5 sibling 3 18
Proband+6 sibling 1 7
Total 580 1494
Table 2: Risk factors in the probands and their siblings with 
premature onset CHD
Risk factor Probands (n = 580) Siblings (n = 786)
Age* 52.0(SD = 7.4) 56.0(SD = 7.8)
Female* 113 (19.5%) 429 (54.6%)
Male* 467 (80.5%) 357 (45.4%)
Non smoker* 116 (20.0%) 328 (41.7%)
Ex smoker* 249 (42.9%) 224 (28.5%)
Current smoker* 215 (37.1%) 234 (29.8%)
Hypertension 
treatment
148 (25.5%) 177 (22.5%)
Systolic BP ≥ 140 
mmHg
30 (5.2%) 239 (30.4%)
Diastolic BP ≥ 95 
mmHg
1 (0.2%) 2 (0.3%)
Total hypertension* 179 (30.9%) 418 (53.2%)
Known diabetes* 53 (9.1%) 43 (5.5%)
Total cholesterol 
(mmol/l)*
4.9(SD = 1.1) 5.8(SD = 1.1)
* P < 0.01, SD – standard deviation.BMC Medical Genetics 2007, 8:62 http://www.biomedcentral.com/1471-2350/8/62
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out the environmental risk factor of interest (such as
smoking status or diabetes).
Although free from the problems of hidden population
stratification, there is a relative lack of power with family
based association studies. The number of families
recruited was 580; however, the number of informative
families ranged from 181 to 323 (Table 3). Of course, we
cannot exclude the possibility that other polymorphisms
in the CFH gene, which are not in linkage disequilibrium
with any of these 6 SNPs, may play a role. However, we
found no association between 6 common SNPs or 5 hap-
lotypes of the CFH gene and early-onset CHD in this Irish
family-based population.
Conclusion
In this family-based study, we found no evidence of an
association between variants of the CFH gene and early-
onset coronary heart disease.
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